Our platform enables multi-year expression of antibody therapeutics from a single administration.
Our proprietary platform was developed and refined by scientists working at leading academic research institutions.
Cure Systems was founded in Cambridge, MA with the mission of creating effective, long-lasting therapeutics for a wide-range of diseases.
Our platform technology has been proven to produce durable expression of antibodies in humans for multiple years.
See phase I results here.We were recently awarded a SBIR contract from the NIH to develop a vaccine against Malaria using our technology.
We are looking for partners interested in developing their biologics into long-lived treatments. Cure Systems provides a full-range of product development services from initial consultation to a fully-integrated drug-development program, including IND-enabling pre-clinical studies.
We have extensive experience delivering neutralizing antibodies against a range of pathogens. Let us leverage our clinically validated gene transfer technology to help you develop new vaccine candidates for previously intractable infectious diseases.
Our platform has been used to deliver over 20 different monoclonal antibodies targeting a wide-range of diseases in vivo. We can use our expertise to convert your proven biologic into novel solutions for cancer, autoimmunity, neurological conditions, inflammation, and more.
Our mission is to create a new kind of drug that is accessible, affordable, easily stored, and long-lasting from just a single administration.
We are an interdisciplinary team focused on harnessing the potential of vectored antibody delivery to solve today's healthcare problems. Together we have decades of research experience spanning the fields of virology, immunology, gene transfer, and regenerative medicine.
Founder
Scientific Co-Founder
Scientific Co-Founder
Principal Scientist